2025 Announcement from International Affairs Committee
-
Regular meeting with the German Association of the Research-based Pharmaceutical Industry (vfa)" was held
-
Special Session at the "12th Nikkei-FT Conference on Infectious Diseases
~Toward Securing Crisis-Response Medicines and Other Products (MCM) for Infectious Diseases -
Cover Letter Template Created for Use in the Simplified Review System in the Asian Region
-
JPMA Media Forum "Two Major Issues in Countermeasures against Infectious Diseases: Consideration of Countermeasures against Drug-Resistant Bacteria and Proper Understanding of Immunization" Report
-
The article of Chairperson Murakami's interview for the Nikkan Yakugyo (Japanese only) is published in the Nikkan Yakugyo (Japanese only)
International Chairperson Murakami strengthens communication to the international community and establishes a new organization. -
The 3rd Japan-Malaysia Symposium on Drug Regulation
Active discussions were held between the two countries on the themes of "Real World Data, Risk Management Plan, Expedited Review (Simplified Review) System, and Clinical Trials. -
The 6th Japan-Korea Symposium on Pharmaceutical Regulation was held.
Pharmaceutical regulatory authorities and industry from Japan and Korea gathered to discuss common issues -
Meeting with Pharmaceuticals and Medical Devices Agency (PMDA), National Cancer Center (NCC), and National Institute of Health Risk Management (JIHS)" held to improve the clinical trial environment in Asia
-
International Affairs Committee" was introduced in JPMA Newsletter No.225.
-
The "Regular Meeting with the French Association of the Pharmaceutical Industry (Leem)" was held
-
Held "Regular Meeting with the European Federation of Pharmaceutical Industries and Associations (EFPIA)
-
The 2nd Neglected Tropical Diseases Contest" was held.
-
Regular meeting with the German Association of the Research-based Pharmaceutical Industry (vfa)" was held
-
Held a special session at the "11th Nikkei-FT Conference on Infectious Diseases
Establishment of an Infectious Drug Discovery Ecosystem - Toward the Implementation Phase